Literature DB >> 25913663

Management of hidradenitis suppurativa: a U.K. survey of current practice.

J R Ingram1, M McPhee2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25913663     DOI: 10.1111/bjd.13866

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

Review 1.  An Update on Medical Treatment Options for Hidradenitis Suppurativa.

Authors:  I E Deckers; E P Prens
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

Review 2.  The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.

Authors:  Ahmed Shah; Raed Alhusayen; Saeid Amini-Nik
Journal:  Inflamm Res       Date:  2017-06-27       Impact factor: 4.575

Review 3.  Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Paul Tappenden; Christopher Carroll; John W Stevens; Andrew Rawdin; Sabine Grimm; Mark Clowes; Eva Kaltenthaler; John R Ingram; Fiona Collier; Mohammad Ghazavi
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

Review 4.  Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.

Authors:  John W Frew; Jason E Hawkes; James G Krueger
Journal:  Ther Adv Chronic Dis       Date:  2019-03-01       Impact factor: 5.091

5.  Secondary prevention of hidradenitis suppurativa.

Authors:  Hjalmar Kurzen; Marina Kurzen
Journal:  Dermatol Reports       Date:  2019-10-25

Review 6.  Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality.

Authors:  J R Ingram; P N Woo; S L Chua; A D Ormerod; N Desai; A C Kai; K Hood; T Burton; F Kerdel; S E Garner; V Piguet
Journal:  Br J Dermatol       Date:  2016-03-30       Impact factor: 9.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.